Chai, Y.; Chen, Y.; Zhang, D.; Wei, Y.; Li, Z.; Li, Q.; Xu, B.
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. J. Pers. Med. 2022, 12, 323.
https://doi.org/10.3390/jpm12020323
AMA Style
Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B.
Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. Journal of Personalized Medicine. 2022; 12(2):323.
https://doi.org/10.3390/jpm12020323
Chicago/Turabian Style
Chai, Yue, Yujie Chen, Di Zhang, Yuce Wei, Zhijun Li, Qiao Li, and Binghe Xu.
2022. "Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis" Journal of Personalized Medicine 12, no. 2: 323.
https://doi.org/10.3390/jpm12020323
APA Style
Chai, Y., Chen, Y., Zhang, D., Wei, Y., Li, Z., Li, Q., & Xu, B.
(2022). Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis. Journal of Personalized Medicine, 12(2), 323.
https://doi.org/10.3390/jpm12020323
